Streetwise Reports' Article Archives — July 2021 back to current month (23)
Sorrento Therapeutics Proceeds with COVID-19 Drug Treatment Trial (07/28/2021)
The latest developments concerning Sorrento Therapeutics, its product portfolio and partners are summarized in a Dawson James Securities report.
Biopharma Creates New Business Unit Ahead of Commercial Product Launch (07/28/2021)
The purpose of HTG Molecular Diagnostics' new therapeutics division and early interest in the biopharma's commercial-ready Transcriptome Panel are covered in an H.C. Wainwright & Co. report.
Rritual Superfoods at Full-Throttle, Adding CVS, Amazon Along the US Distribution Superhighway (07/28/2021)
Knox Henderson takes a close look at Rritual Superfoods and its plans to ramp up mass distribution.
Tilray Shares Fly High on Strong Q4 and FY Revenue Growth (07/28/2021)
Shares of Tilray Inc. traded 25% higher after the company reported FY/21 financial results that included a 27% YoY increase in net revenues to $513.1 million driven by a 55% growth in cannabis revenue following its Aphria acquisition.
Cannabis Market Delivering for Consumers and Investors (07/21/2021)
As legalization takes hold across the U.S., opportunities for the next generation of cannabis companies expand. Adrian Morante of K2 & Associates finds “trustworthy, capable and reputable” companies with value.
Coverage Initiated on Company with a 'Genuine Physiological Heart Replacement Therapy' (07/21/2021)
The investment thesis for the device company Carmat, whose therapy "allows patients to live with almost normal quality of life," is presented in an H.C. Wainwright & Co. report.
Biopharma Partners with NIH to Advance Women's Hormone-Free Contraceptive (07/21/2021)
A Roth Capital Partners report calls this a "very cost-effective and strategic move" for Daré Bioscience.
Rapidly Growing Virtual Healthcare Firm Adds Three New US Group Medical Practice Clients (07/21/2021)
Reliq Health Technologies advised it entered into agreements with three physician practices in Texas for its iUGO Care platform.
HCA Healthcare Shares Gain 15% on Strong Q2 Performance and Raised FY Outlook (07/20/2021)
HCA Healthcare shares established a new 52-week high after the company reported a greater than 30% increase in YoY revenue in Q2/21.
Small Bio-tech Gets $17.7 Million Backing from U.S. Department of Defense to Treat SARS-CoV-2 Delta Variant (07/20/2021)
Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets.
Cytokinetics Shares Rise 41% on Positive Phase 2 Redwood-HCM Trial Data (07/19/2021)
Cytokinetics Inc. shares reached a new 52-week high after the company reported positive topline results from its Phase 2 CK-274 hypertrophic cardiomyopathy clinical trial.
Zynex Shares Rise as Firm Notches Significant Q2 Order Growth and Raises EBITDA Outlook (07/16/2021)
Zynex Inc. shares traded 10% higher after the electrotherapy medical device maker reported a 247% YoY growth in orders during Q2/21 and raised the range for its EBITDA estimates in the quarter by $1.2 million.
Merger of Two Biopharmas 'Brings a New Dawn' (07/14/2021)
The implications of the Aerpio Pharmaceuticals–Aadi Bioscience transaction and the outlook and future for the combined company's lead drug candidate are discussed in an H.C. Wainwright & Co. report.
FDA, EMA Approve Drug Firm's Phase 3 Liver Cancer Trial Design (07/14/2021)
The recent news regarding Can-Fite BioPharma is reviewed in a Dawson James Securities report.
US Cannabis Sales Hold Strong as Industry Lays Out New Lobbying Efforts to Expedite Federal Reform (07/14/2021)
McAlinden Research Partners expects activity and revenues in the cannabis space to continue ramping up as the US crosses the point at which legalization is not a question of "if" but "when."
Alphatec Shares Rise After Firm Announces Strong Organic Revenue Growth in Q2 (07/12/2021)
Alphatec Holdings Inc. shares traded 12% higher after the company reported preliminary Q2/21 financial results that included a larger than 90% increase in YoY organic revenue.
Pharma Company Working to Unlock Psychedelic Drug's Potential for Stroke Recovery (07/09/2021)
Algernon Pharmaceuticals CEO Christopher J. Moreau and Dr. David Nutt, the company's research stroke consultant, discuss Algernon's upcoming Phase 1 study of DMT for stroke.
Biopharma Files New Drug Application for Lead Clinical Product (07/07/2021)
A review of Daré Bioscience's lead clinical product for bacterial vaginosis and a potential timeline to commercialization are provided in a Roth Capital Partners report.
Biotech 'Strikes Again,' Identifies Gene Mutation that Protects Against Obesity (07/07/2021)
The encouraging work Regeneron Pharmaceuticals completed thus far, and the next challenge in this program, are laid out in an H.C. Wainwright & Co. report.
Biohaven Posts Revenue of $93 Million in Q2 for Its Migraine Medicine (07/07/2021)
Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded 12% higher to a new 52-week high after the company reported preliminary Q2/21 net product revenue of $93 million for NURTEC ODT, which it claims is the first and only FDA approved medicine for both acute and preventive migraine treatment.
ALX Oncology Shares Rise on Positive Response and Survival Data in Phase 1b Gastric Cancer Trial (07/06/2021)
Shares of ALX Oncology Holdings Inc. traded 10% higher after the company reported new data from its Phase 1b ASPEN-01 study of ALX148 demonstrated a robust objective response in patients with gastric or gastroesophageal junction cancer.
Alector Partners with GSK to Develop Monoclonal Antibodies for Neurodegenerative Diseases (07/02/2021)
Alector Inc. shares traded 59% higher after the company announced it entered into a global collaboration agreement with GlaxoSmithKline to develop and advance two first-in-class, clinical stage monoclonal antibodies for treating neurodegenerative diseases including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's and Alzheimer's.
Pulse Bio Shares Beat Higher on Launch of CellFX NPS System in Canada (07/01/2021)
Pulse Biosciences shares traded 27% higher after the company announced it secured a $50 million private placement one day after it reported the first CellFX® procedure using its proprietary Nano-Pulse Stimulation technology had been performed in Canada.
More Archives
2024Nov Oct Sep Aug Jul Jun May Apr Mar Feb Jan
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
